Topics:

Lung Cancer

ASCO Endorses Lung Cancer Guidelines for Molecular Testing

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

Lung Cancer

Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.

NLST data clearly demonstrate that lung cancer screening is effective and safe and reduces lung cancer-specific mortality by at least 20%. There is no possible reason for CMS to further delay or restrict lung cancer screening for those at high risk.

The development of CT lung cancer screening, the publication of results from the NLST in 2011, and the grade-B recommendation for CT lung cancer screening in high-risk smokers by the USPSTF raise a number of interesting national health policy issues.

The NLST is a landmark trial demonstrating that implementation of low-dose CT screening lowers lung cancer–related mortality. We must put the study results and cost-effectiveness analyses in the context of the staggering statistics: up to 65% of lung cancer patients present with advanced-stage disease where treatments are often costly, toxic, and only palliative in nature.

American medicine is poised for an expanded conflict over the assumption and consequences of risk in medical care.

A small trial yielded “dramatic” results with high progression-free and overall survival using SBRT along with erlotinib for patients with stage IV lung cancer.

The Centers for Medicare & Medicaid Services announced plans to cover low-dose CT screening for lung cancer, based mainly on the National Lung Screening Trial.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.